Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide

Mariellen J. Moore, Yan Gong, Wei Hou, Karen Hall, Siegfried O F Schmidt, Robert Whitney Curry, Amber L. Beitelshees, Arlene Chapman, Stephen T Turner, Gary Lee Schwartz, Kent R Bailey, Eric Boerwinkle, John G. Gums, Rhonda M. Cooper-Dehoff, Julie A. Johnson

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Study Objective To develop and validate a predictive model for glucose change and risk for new-onset impaired fasting glucose in hypertensive participants following treatment with atenolol or hydrochlorothiazide (HCTZ).

Design Randomized multicenter clinical trial.

Patients A total of 735 white or African-American men and women with uncomplicated hypertension.

Measurements and Main Results Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) is a randomized clinical trial to assess the genetic and nongenetic predictors of blood pressure response and adverse metabolic effects following treatment with atenolol or HCTZ. To develop and validate predictive models for glucose change, PEAR participants were randomly divided into a derivation cohort of 367 and a validation cohort of 368. Linear and logistic regression modeling were used to build models of drug-associated glucose change and impaired fasting glucose (IFG), respectively, in the derivation cohorts. These models were then evaluated in the validation cohorts. For glucose change after atenolol or HCTZ treatment, baseline glucose was a significant (p<0.0001) predictor, explaining 13% of the variability in glucose change after atenolol and 12% of the variability in glucose change after HCTZ. Baseline glucose was also the strongest and most consistent predictor (p<0.0001) for development of IFG after atenolol or HCTZ monotherapy. The area under the receiver operating curve was 0.77 for IFG after atenolol and 0.71 after HCTZ treatment, respectively.

Conclusion Baseline glucose is the primary predictor of atenolol or HCTZ-associated glucose increase and development of IFG after treatment with either drug.

Original languageEnglish (US)
Pages (from-to)1132-1140
Number of pages9
JournalPharmacotherapy
Volume34
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Hydrochlorothiazide
Atenolol
Glucose
Fasting
Therapeutics
Pharmacogenetics
Antihypertensive Agents
Randomized Controlled Trials
Pharmaceutical Preparations
African Americans
Multicenter Studies

Keywords

  • atenolol
  • hydrochlorothiazide
  • hyperglycemia
  • impaired fasting glucose
  • thiazide diuretics
  • β-Blockers

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Moore, M. J., Gong, Y., Hou, W., Hall, K., Schmidt, S. O. F., Curry, R. W., ... Johnson, J. A. (2014). Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide. Pharmacotherapy, 34(11), 1132-1140. https://doi.org/10.1002/phar.1483

Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide. / Moore, Mariellen J.; Gong, Yan; Hou, Wei; Hall, Karen; Schmidt, Siegfried O F; Curry, Robert Whitney; Beitelshees, Amber L.; Chapman, Arlene; Turner, Stephen T; Schwartz, Gary Lee; Bailey, Kent R; Boerwinkle, Eric; Gums, John G.; Cooper-Dehoff, Rhonda M.; Johnson, Julie A.

In: Pharmacotherapy, Vol. 34, No. 11, 01.11.2014, p. 1132-1140.

Research output: Contribution to journalArticle

Moore, MJ, Gong, Y, Hou, W, Hall, K, Schmidt, SOF, Curry, RW, Beitelshees, AL, Chapman, A, Turner, ST, Schwartz, GL, Bailey, KR, Boerwinkle, E, Gums, JG, Cooper-Dehoff, RM & Johnson, JA 2014, 'Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide', Pharmacotherapy, vol. 34, no. 11, pp. 1132-1140. https://doi.org/10.1002/phar.1483
Moore, Mariellen J. ; Gong, Yan ; Hou, Wei ; Hall, Karen ; Schmidt, Siegfried O F ; Curry, Robert Whitney ; Beitelshees, Amber L. ; Chapman, Arlene ; Turner, Stephen T ; Schwartz, Gary Lee ; Bailey, Kent R ; Boerwinkle, Eric ; Gums, John G. ; Cooper-Dehoff, Rhonda M. ; Johnson, Julie A. / Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide. In: Pharmacotherapy. 2014 ; Vol. 34, No. 11. pp. 1132-1140.
@article{1e8c6bb628e1422ca751329518fed5f4,
title = "Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide",
abstract = "Study Objective To develop and validate a predictive model for glucose change and risk for new-onset impaired fasting glucose in hypertensive participants following treatment with atenolol or hydrochlorothiazide (HCTZ).Design Randomized multicenter clinical trial.Patients A total of 735 white or African-American men and women with uncomplicated hypertension.Measurements and Main Results Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) is a randomized clinical trial to assess the genetic and nongenetic predictors of blood pressure response and adverse metabolic effects following treatment with atenolol or HCTZ. To develop and validate predictive models for glucose change, PEAR participants were randomly divided into a derivation cohort of 367 and a validation cohort of 368. Linear and logistic regression modeling were used to build models of drug-associated glucose change and impaired fasting glucose (IFG), respectively, in the derivation cohorts. These models were then evaluated in the validation cohorts. For glucose change after atenolol or HCTZ treatment, baseline glucose was a significant (p<0.0001) predictor, explaining 13{\%} of the variability in glucose change after atenolol and 12{\%} of the variability in glucose change after HCTZ. Baseline glucose was also the strongest and most consistent predictor (p<0.0001) for development of IFG after atenolol or HCTZ monotherapy. The area under the receiver operating curve was 0.77 for IFG after atenolol and 0.71 after HCTZ treatment, respectively.Conclusion Baseline glucose is the primary predictor of atenolol or HCTZ-associated glucose increase and development of IFG after treatment with either drug.",
keywords = "atenolol, hydrochlorothiazide, hyperglycemia, impaired fasting glucose, thiazide diuretics, β-Blockers",
author = "Moore, {Mariellen J.} and Yan Gong and Wei Hou and Karen Hall and Schmidt, {Siegfried O F} and Curry, {Robert Whitney} and Beitelshees, {Amber L.} and Arlene Chapman and Turner, {Stephen T} and Schwartz, {Gary Lee} and Bailey, {Kent R} and Eric Boerwinkle and Gums, {John G.} and Cooper-Dehoff, {Rhonda M.} and Johnson, {Julie A.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1002/phar.1483",
language = "English (US)",
volume = "34",
pages = "1132--1140",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "11",

}

TY - JOUR

T1 - Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide

AU - Moore, Mariellen J.

AU - Gong, Yan

AU - Hou, Wei

AU - Hall, Karen

AU - Schmidt, Siegfried O F

AU - Curry, Robert Whitney

AU - Beitelshees, Amber L.

AU - Chapman, Arlene

AU - Turner, Stephen T

AU - Schwartz, Gary Lee

AU - Bailey, Kent R

AU - Boerwinkle, Eric

AU - Gums, John G.

AU - Cooper-Dehoff, Rhonda M.

AU - Johnson, Julie A.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Study Objective To develop and validate a predictive model for glucose change and risk for new-onset impaired fasting glucose in hypertensive participants following treatment with atenolol or hydrochlorothiazide (HCTZ).Design Randomized multicenter clinical trial.Patients A total of 735 white or African-American men and women with uncomplicated hypertension.Measurements and Main Results Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) is a randomized clinical trial to assess the genetic and nongenetic predictors of blood pressure response and adverse metabolic effects following treatment with atenolol or HCTZ. To develop and validate predictive models for glucose change, PEAR participants were randomly divided into a derivation cohort of 367 and a validation cohort of 368. Linear and logistic regression modeling were used to build models of drug-associated glucose change and impaired fasting glucose (IFG), respectively, in the derivation cohorts. These models were then evaluated in the validation cohorts. For glucose change after atenolol or HCTZ treatment, baseline glucose was a significant (p<0.0001) predictor, explaining 13% of the variability in glucose change after atenolol and 12% of the variability in glucose change after HCTZ. Baseline glucose was also the strongest and most consistent predictor (p<0.0001) for development of IFG after atenolol or HCTZ monotherapy. The area under the receiver operating curve was 0.77 for IFG after atenolol and 0.71 after HCTZ treatment, respectively.Conclusion Baseline glucose is the primary predictor of atenolol or HCTZ-associated glucose increase and development of IFG after treatment with either drug.

AB - Study Objective To develop and validate a predictive model for glucose change and risk for new-onset impaired fasting glucose in hypertensive participants following treatment with atenolol or hydrochlorothiazide (HCTZ).Design Randomized multicenter clinical trial.Patients A total of 735 white or African-American men and women with uncomplicated hypertension.Measurements and Main Results Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) is a randomized clinical trial to assess the genetic and nongenetic predictors of blood pressure response and adverse metabolic effects following treatment with atenolol or HCTZ. To develop and validate predictive models for glucose change, PEAR participants were randomly divided into a derivation cohort of 367 and a validation cohort of 368. Linear and logistic regression modeling were used to build models of drug-associated glucose change and impaired fasting glucose (IFG), respectively, in the derivation cohorts. These models were then evaluated in the validation cohorts. For glucose change after atenolol or HCTZ treatment, baseline glucose was a significant (p<0.0001) predictor, explaining 13% of the variability in glucose change after atenolol and 12% of the variability in glucose change after HCTZ. Baseline glucose was also the strongest and most consistent predictor (p<0.0001) for development of IFG after atenolol or HCTZ monotherapy. The area under the receiver operating curve was 0.77 for IFG after atenolol and 0.71 after HCTZ treatment, respectively.Conclusion Baseline glucose is the primary predictor of atenolol or HCTZ-associated glucose increase and development of IFG after treatment with either drug.

KW - atenolol

KW - hydrochlorothiazide

KW - hyperglycemia

KW - impaired fasting glucose

KW - thiazide diuretics

KW - β-Blockers

UR - http://www.scopus.com/inward/record.url?scp=84908886185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908886185&partnerID=8YFLogxK

U2 - 10.1002/phar.1483

DO - 10.1002/phar.1483

M3 - Article

VL - 34

SP - 1132

EP - 1140

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 11

ER -